Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Medicine
Published in: BMC Medicine 1/2017

Open Access 01-12-2017 | Research article

Daily home fortification with iron as ferrous fumarate versus NaFeEDTA: a randomised, placebo-controlled, non-inferiority trial in Kenyan children

Authors: Emily M. Teshome, Pauline E. A. Andang’o, Victor Osoti, Sofie R. Terwel, Walter Otieno, Ayşe Y. Demir, Andrew M. Prentice, Hans Verhoef

Published in: BMC Medicine | Issue 1/2017

Login to get access

Abstract

Background

We aimed to show the non-inferiority of home fortification with a daily dose of 3 mg iron in the form of iron as ferric sodium ethylenediaminetetraacetate (NaFeEDTA) compared with 12.5 mg iron as encapsulated ferrous fumarate in Kenyan children aged 12–36 months. In addition, we updated a recent meta-analysis to assess the efficacy of home fortification with iron-containing powders, with a view to examining diversity in trial results.

Methods

We gave chemoprevention by dihydroartemisinin-piperaquine, albendazole and praziquantel to 338 afebrile children with haemoglobin concentration ≥70 g/L. We randomly allocated them to daily home fortification for 30 days with either placebo, 3 mg iron as NaFeEDTA or 12.5 mg iron as encapsulated ferrous fumarate. We assessed haemoglobin concentration (primary outcome), plasma iron markers, plasma inflammation markers and Plasmodium infection in samples collected at baseline and after 30 days of intervention. We conducted a meta-analysis of randomised controlled trials in pre-school children to assess the effect of home fortification with iron-containing powders on anaemia and haemoglobin concentration at end of intervention.

Results

A total of 315 children completed the 30-day intervention period. At baseline, 66.9% of children had inflammation (plasma C-reactive protein concentration >5 mg/L or plasma α 1-acid glycoprotein concentration >1.0 g/L); in those without inflammation, 42.5% were iron deficient. There was no evidence, either in per protocol analysis or intention-to-treat analysis, that home fortification with either of the iron interventions improved haemoglobin concentration, plasma ferritin concentration, plasma transferrin receptor concentration or erythrocyte zinc protoporphyrin-haem ratio. We also found no evidence of effect modification by iron status, anaemia status and inflammation status at baseline. In the meta-analysis, the effect on haemoglobin concentration was highly heterogeneous between trials (I 2: 84.1%; p value for test of heterogeneity: <0.0001).

Conclusions

In this population, home fortification with either 3 mg iron as NaFeEDTA or 12.5 mg iron as encapsulated ferrous fumarate was insufficiently efficacious to assess non-inferiority of 3 mg iron as NaFeEDTA compared to 12.5 mg iron as encapsulated ferrous fumarate. Our finding of heterogeneity between trial results should stimulate subgroup analysis or meta-regression to identify population-specific factors that determine efficacy.

Trial Registration

The trial was registered with ClinicalTrials.gov (NCT02073149) on 25 February 2014.
Appendix
Available only for authorised users
Literature
1.
2.
3.
De-Regil LM, Suchdev PS, Vist GE, Walleser S, Peña-Rosas JP. Home fortification of foods with multiple micronutrient powders for health and nutrition in children under two years of age. Cochrane Database Syst Rev. 2011;9:CD008959.
4.
5.
Salam RA, MacPhail C, Das JK, Bhutta ZA. Effectiveness of micronutrient powders (MNP) in women and children. BMC Public Health. 2013;13(Suppl3):S22.PubMedPubMedCentral
6.
Soofi S, Cousens S, Iqbal SP, Akhund T, Khan J, Ahmed I, Zaidi AKM, Bhutta ZA. Effect of provision of daily zinc and iron with several micronutrients on growth and morbidity among young children in Pakistan: a cluster-randomised trial. Lancet. 2013;382:29–40.CrossRefPubMed
7.
Jaeggi T, Kortman GA, Moretti D, Chassard C, Holding P, Dostal A, Boekhorst J, Timmerman HM, Swinkels DW, Tjalsma H, Njenga J, Mwangi A, Kvalsvig J, Lacroix C, Zimmermann MB. Iron fortification adversely affects the gut microbiome, increases pathogen abundance and induces intestinal inflammation in Kenyan infants. Gut. 2015;64:731–42.CrossRefPubMed
8.
Zlotkin S, Newton S, Aimone AM, Azindow I, Amenga-Etego S, Tchum K, Mahama E, Thorpe KE, Owusu-Agyei S. Effect of iron fortification on malaria incidence in infants and young children in Ghana: a randomized trial. JAMA. 2013;310:938–47.CrossRefPubMed
9.
10.
Kortman GAM, Boleij A, Swinkels DW, Tjalsma H. Iron availability increases the pathogenic potential of Salmonella typhimurium and other enteric pathogens at the intestinal epithelial interface. PLoS One. 2012;7:e29968.CrossRefPubMedPubMedCentral
11.
Zimmermann MB, Chassard C, Rohner F, N’goran EK, Nindjin C, Dostal A, Utzinger J, Ghattas H, Lacroix C, Hurrell RF. The effects of iron fortification on the gut microbiota in African children: a randomized controlled trial in Cote d’Ivoire. Am J Clin Nutr. 2010;92:1406–15.CrossRefPubMed
12.
Gill SK, Nguyen P, Koren G. Adherence and tolerability of iron-containing prenatal multivitamins in pregnant women with pre-existing gastrointestinal conditions. J Obstet Gynaecol. 2009;29:594–8.CrossRefPubMed
13.
Sölvell L. Oral iron therapy. Side effects. In: Hallberg L, Harwerth H-G, Vannotti A, editors. Iron deficiency: pathogenesis, clinical aspects, therapy. London: Academic Press; 1970. p. 573–83.
14.
De Melo Machado KM, Cardoso Ferreira LO, Impieri de Souza A, Da Silva Diniz A. The side-effects of different doses of iron sulfate on women of reproductive age: a randomized double-blind, placebo-controlled study. Rev Bras Saude Mater Infant. 2011;11:275–81.CrossRef
15.
Kumar N, Chandhiok N, Dhillon BS, Kumar P. Role of oxidative stress while controlling iron deficiency anaemia during pregnancy — Indian scenario. Indian J Clin Biochem. 2009;24:5–14.CrossRefPubMedPubMedCentral
16.
Verhoef H, Veenemans J. Safety of iron-fortified foods in malaria-endemic areas. Am J Clin Nutr. 2009;89:1949–50.CrossRefPubMed
17.
Ministry of Public Health and Sanitation. Kenya National Malaria Strategy Plan 2010–2017. Nairobi: Ministry of Public Health and Sanitation; 2009.
18.
Ministry of Health. Kenya Annual Malaria Report 2012–2013. Nairobi: Ministry of Health; 2013.
19.
Munyekenye OG, Githeko AK, Zhou G, Mushinzimana E, Minakawa N, Yan G. Plasmodium falciparum spatial analysis, western Kenya highlands. Emerg Infect Dis. 2005;11:1571–7.CrossRefPubMedPubMedCentral
20.
Desai MR, Dhar R, Rosen DH, Kariuki SK, Shi YP, Kager PA, Ter Kuile FO. Daily iron supplementation is more efficacious than twice weekly iron supplementation for the treatment of childhood anaemia in western Kenya. J Nutr. 2004;134:1167–74.PubMed
21.
Desai MR, Mei JV, Kariuki SK, Wannemuehler KA, Phillips-Howard PA, Nahlen BL, Kager PA, Vulule JM, ter Kuile FO. Randomized, controlled trial of daily iron supplementation and intermittent sulfadoxine-pyrimethamine for the treatment of mild childhood anaemia in western Kenya. J Infect Dis. 2003;187:658–66.CrossRefPubMed
22.
Terlouw DJ, Desai MR, Wannemuehler KA, Kariuki SK, Pfeiffer CM, Kager PA, Shi YP, Ter Kuile FO. Relation between the response to iron supplementation and sickle cell haemoglobin phenotype in preschool children in western Kenya. Am J Clin Nutr. 2004;79:466–72.PubMed
23.
24.
25.
26.
Tarning J, Zongo I, Some FA, Rouamba N, Parikh S, Rosenthal PJ. Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Clin Pharmacol Therap. 2012;91:497–505.CrossRef
27.
28.
White NJ. How antimalarial drug resistance affects post-treatment prophylaxis. Malaria J. 2008;7:9.CrossRef
29.
D’Agostino RB, Massaro JM, Sullivan LM. Non-inferiority trials: design concepts and issues — the encounters of academic consultants in statistics. Stat Med. 2003;22:169–86.CrossRefPubMed
30.
31.
32.
Okebe JU, Yahav D, Shbita R, Paul M. Oral iron supplements for children in malaria-endemic areas. Cochrane Database Syst Rev. 2011;10:CD006589.
33.
34.
Verhoef H, Veenemans J, Mwangi MN, Prentice AM. Safety and benefits of interventions to improve folate status in malaria-endemic areas. Brit J Haematol. (Accepted for publication).
35.
Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA. 1989;261:3273–377.CrossRefPubMed
36.
Vrijens B, Urquhart J. Patient adherence to prescribed antimicrobial drug dosing regimens. J Antimicrob Chemother. 2005;55:616–27.CrossRefPubMed
37.
Hallberg L, Rossander L, Skanberg AB. Phytates and the inhibitory effect of bran on iron absorption in man. Am J Clin Nutr. 1987;45:988–96.CrossRefPubMed
38.
Hurrell RF, Reddy MB, Juillerat MA, Cook JD. Degradation of phytic acid in cereal porridges improves iron absorption by human subjects. Am J Clin Nutr. 2003;77:1213–9.PubMed
39.
40.
41.
42.
43.
44.
Abraham K, Muller C, Gruters A, Wahn U, Schweigert FJ. Minimal inflammation, acute phase response and avoidance of misclassification of vitamin A and iron status in infants—importance of a high-sensitivity C-reactive protein (CRP) assay. Int J Vitam Nutr Res. 2003;73:423–30.CrossRefPubMed
45.
Ayoya MA, Spiekermann-Brouwer GM, Stoltzfus RJ, Nemeth E, Habicht JP, Ganz T, Rawat R, Traoré AK, Garza C. Acid glycoprotein, hepcidin, C-reactive protein, and serum ferritin are correlated in anemic schoolchildren with Schistosoma haematobium. Am J Clin Nutr. 2010;91:1784–90.CrossRefPubMed
46.
Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA. 1989;261:3273–7.CrossRefPubMed
47.
48.
Suchdev PS, Namaste SM, Aaron GJ, Raiten DJ, Brown KH, Flores-Ayala R, BRINDA Working Group. Overview of the Biomarkers Reflecting Inflammation and Nutritional Determinants of Anemia (BRINDA) project. Adv Nutr. 2016;7:349–56.CrossRefPubMedPubMedCentral
49.
Malvy DJ, Povéda JD, Debruyne M, Montagnon B, Burtschy B, Herbert C, Cacès P, Houot O, Amédée-Manesme O. Laser immunonephelometry reference intervals for eight serum proteins in healthy children. Clin Chem. 1992;38:394–9.PubMed
50.
51.
Ragland DR. Dichotomizing continuous outcome variables: dependence of the magnitude of association and statistical power on the cutpoint. Epidemiology. 1992;3:434–40.CrossRefPubMed
52.
Marquart L, Butterworth A, McCarthy JS, Gatton ML. Modelling the dynamics of Plasmodium falciparum histidine-rich protein 2 in human malaria to better understand malaria rapid diagnostic test performance. Malar J. 2012;11:74.CrossRefPubMedPubMedCentral
53.
Aydin-Schmidt B, Mubi M, Morris U, Petzold M, Ngasala BE, Premji Z, Björkman A, Mårtensson A. Usefulness of Plasmodium falciparum-specific rapid diagnostic tests for assessment of parasite clearance and detection of recurrent infections after artemisinin-based combination therapy. Malar J. 2013;12:349.CrossRefPubMedPubMedCentral
54.
55.
Zongo I, Milligan P, Compaore YD, Some AF, Greenwood B, Tarning J, Rosenthal PJ, Sutherland C, Nosten F, Ouedraogoa J-B. Randomized noninferiority trial of dihydroartemisinin-piperaquine compared with sulfadoxine-pyrimethamine plus amodiaquine for seasonal malaria chemoprevention in Burkina Faso. Antimicrob Agents Chemother. 2015;59:4387–96.CrossRefPubMedPubMedCentral
56.
Wreesmann CTJ. Reasons for raising the maximum acceptable daily intake of EDTA and the benefits for iron fortification of foods for children 6–24 months of age. Matern Child Nutr. 2014;10:481–95.CrossRefPubMedPubMedCentral
57.
Bouhouch RR, El-Fadeli S, Andersson M, Aboussad A, Chabaa L, Zeder C, Kippler M, Baumgartner J, Sedki A, Zimmermann MB. Effects of wheat-flour biscuits fortified with iron and EDTA, alone and in combination, on blood lead concentration, iron status, and cognition in children: a double-blind randomized controlled trial. Am J Clin Nutr. 2016;104:1318–26.CrossRefPubMed
58.
Verhoef H, West CE, Nzyuko SM, de Vogel S, van der Valk R, Wanga MA, Kuijsten A, Veenemans J, Kok FJ. Intermittent administration of iron and sulfadoxine-pyrimethamine to control anaemia in Kenyan children: a randomised controlled trial. Lancet. 2002;360:908–14.CrossRefPubMed
59.
Barth-Jaeggi T, Moretti D, Kvalsvig J, Holding PA, Njenga J, Mwangi A, Chhagan MK, Lacroix C, Zimmermann MB. In-home fortification with 2.5 mg iron as NaFeEDTA does not reduce anaemia but increases weight gain: a randomised controlled trial in Kenyan infants. Matern Child Nutr. 2015;11 Suppl 4:151–62.CrossRefPubMed
60.
Zlotkin S, Antwi KY, Schauer C, Yeung G. Use of microencapsulated iron(II) fumarate sprinkles to prevent recurrence of anaemia in infants and young children at high risk. Bull World Health Organ. 2003;81:108–11.PubMedPubMedCentral
61.
Prentice AM, Doherty CP, Abrams SA, Cox SE, Atkinson SH, Verhoef H, Armitage AE, Drakesmith H. Hepcidin is the major predictor of erythrocyte iron incorporation in anemic African children. Blood. 2012;119:1922–8.CrossRefPubMedPubMedCentral
62.
Rothman KJ, Michels KB. The continuing unethical use of placebo controls. N Engl J Med. 1994;331:394–8.CrossRefPubMed
63.
Van der Graaf R, Rid A. Placebo-controlled trials, ethics of. In: Wright JD, editor. International encyclopedia of the social & behavioral sciences, vol. 18. 2nd ed. Oxford: Elsevier; 2015. p. 164–73.CrossRef
64.
World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–4.CrossRef
65.
LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med. 1997;337:536–42.CrossRefPubMed
66.
Villar J, Carroli G, Belizan JM. Predictive ability of meta-analyses of randomised controlled trials. Lancet. 1995;345:772–6.CrossRefPubMed
67.
Metadata
Title
Daily home fortification with iron as ferrous fumarate versus NaFeEDTA: a randomised, placebo-controlled, non-inferiority trial in Kenyan children
Authors
Emily M. Teshome
Pauline E. A. Andang’o
Victor Osoti
Sofie R. Terwel
Walter Otieno
Ayşe Y. Demir
Andrew M. Prentice
Hans Verhoef
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2017
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/s12916-017-0839-z

Other articles of this Issue 1/2017

BMC Medicine 1/2017 Go to the issue

Research article

Risk and predictors of psoriasis in patients with breast cancer: a Swedish population-based cohort study

Research article

Prediction of complications in early-onset pre-eclampsia (PREP): development and external multinational validation of prognostic models

Research article

Predicting fitness to practise events in international medical graduates who registered as UK doctors via the Professional and Linguistic Assessments Board (PLAB) system: a national cohort study

Research article

Impact of gut hormone FGF-19 on type-2 diabetes and mitochondrial recovery in a prospective study of obese diabetic women undergoing bariatric surgery

Research article

A comparison of liquid and solid culture for determining relapse and durable cure in phase III TB trials for new regimens

Commentary

Humanitarian and primary healthcare needs of refugee women and children in Afghanistan